The CXCR1/2 Pathway: Involvement in Diabetes Pathophysiology and Potential Target for T1D Interventions

Area of Science:

• Immunology and Endocrinology
• Molecular and Cellular Biology

Background:

• Type 1 diabetes (T1D) pathogenesis involves multiple chemokine/chemokine receptor pathways.
• The CXCR1/2 axis is critical for leukocyte recruitment, contributing to insulitis and beta cell damage in T1D.
• Existing CXCR1/2 blocking strategies, initially used in cancer, are now explored for T1D intervention.

Purpose of the Study:

• To investigate the role of CXCR1/2 axis inhibition in preventing T1D-associated pancreatic islet damage.
• To evaluate the therapeutic potential of targeting CXCR1/2 for T1D management.

Main Methods:

• Utilized strategies to block the CXCR1/2 pathway, including neutralizing antibodies, small molecules, and peptide inhibitors.
• Assessed the impact of CXCR1/2 inhibition on the migration of CXCR1/2-expressing cells, such as neutrophils and macrophages.
• Examined the prevention of inflammation- and autoimmunity-mediated damage to pancreatic islets.

Main Results:

• CXCR1/2 inhibition effectively prevents inflammation- and autoimmunity-mediated damage to pancreatic islets.
• Inhibition blocks the migration of key CXCR1/2-expressing cells, including neutrophils and macrophages.
• Demonstrates the significant role of innate immunity in the autoimmune process of T1D.

Conclusions:

• Targeting the CXCR1/2 axis represents a novel and promising interventional strategy for type 1 diabetes.
• CXCR1/2 inhibition offers a potential therapeutic approach by modulating immune cell infiltration in pancreatic islets.
• These findings underscore the importance of innate immune cells in T1D pathogenesis and suggest new avenues for treatment.